Bone Biologics Corporation (BBLG)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | ||||
| Operating Income | -748K | -715K | -733K | -805K |
| Net Income | -741K | -667K | -685K | -766K |
| Diluted EPS | $-1.33 | $-0.37 | $nan | $-0.43 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | |||
| Operating Income | -3.7M | -9.4M | -4.2M | -3.2M |
| Net Income | -1.5M | -8.9M | -4.1M | -3.1M |
| Diluted EPS | $-186.90 | $-204.06 | $-28.96 | $-2.65 |